Published financial brief
4012B
CRESCENT BIOPHARMA INC
- As of
- 2024-12-31
- Source
- Supabase fundamentals
- Calculator
- financial-roic-1.0.0
- Published
- 7/26/2026
4 data notes
- Input provenance requires review.
- A ratio denominator is near zero.
- One or more values are unavailable.
- A displayed ratio exceeds the warning bound.
Exact-period record
Fundamentals
5 reported periods
| Metric | FY 20202020-12-31 | FY 20212021-12-31 | FY 20222022-12-31 | FY 20232023-12-31 | FY 20242024-12-31 |
|---|---|---|---|---|---|
| Financial statements | |||||
| RevenueUSD millions | 10.2 | 1.2 | 0.1 | 0 | 0 |
| Cost of goods soldUSD millions | 61.4 | 64.3 | 47.3 | 39.1 | 32.5 |
| Selling, general and administrative expenseUSD millions | —missing | —missing | —missing | —missing | —missing |
| Depreciation and amortizationUSD millions | 0.3 | 0.3 | 0.2 | 0.2 | 0 |
| Net incomeUSD millions | -51 | -63.4 | -46.7 | -36.9 | -37.9 |
| Operating profit (EBIT)USD millions | -51.5 | -63.4 | -47.4 | -39.3 | -32.5 |
| Income taxesUSD millions | 0 | 0 | 0 | 0 | 0 |
| Short-term debtUSD millions | 0.9 | 1 | 0.9 | 0.7 | 0.1 |
| Long-term debtUSD millions | 1.9 | 0.9 | 0 | 0.1 | 0 |
| Cash and equivalentsUSD millions | 137 | 90.3 | 47.9 | 41.8 | 10.7 |
| ReceivablesUSD millions | 0 | 0 | 0.1 | 0.2 | 0 |
| InventoryUSD millions | 0 | 0 | 0 | 0 | 0 |
| PayablesUSD millions | 2.1 | 2.1 | 1 | 0.9 | 0.3 |
| Net property, plant and equipmentUSD millions | 2.9 | 1.9 | 1 | 0.8 | 0 |
| Capital expenditureUSD millions | 0.1 | 0 | 0.1 | 0 | 0 |
| Operating cash flowUSD millions | -39.2 | -57.5 | -46.5 | -34.9 | -31.1 |
| Prepaid expensesUSD millions | 1.2 | 0.5 | 2.7 | 1.8 | 0.2 |
| AccrualsUSD millions | 9.4 | 8.7 | 7 | 5.2 | 5.4 |
| EBITDAUSD millions | -51.2 | -63.2 | -47.2 | -39.1 | -32.5 |
| Working capitalUSD millions | 125.8 | 79 | 41.8 | 37 | 5.3 |
| Working capital requirementUSD millions | -2.1 | -2.1 | -0.8 | -0.7 | -0.3 |
| Total debtUSD millions | 2.8 | 1.9 | 0.9 | 0.8 | 0.1 |
| Free cash flowUSD millions | -39.3 | -57.5 | -46.5 | -34.9 | -31.1 |
| Unlevered free cash flowUSD millions | -50.5 | -63.2 | -48.6 | -39.3 | -32.8 |
| Returns and ratios | |||||
| ROICratio | -6,003.5% | 39,165% | -28,217% | -51,006% | 9,881.2% |
| Pre-tax ROICratio | -6,003.5% | 39,165% | -28,217% | -51,006% | 9,881.2% |
| Effective tax rateratio | 0% | 0% | 0% | 0% | 0% |
| Revenue growthratio | —missing | -88.6% | -93.5% | -86.7% | -100% |
| EBIT / Revenueratio | -506.8% | -5,469.6% | -63,205% | -392,750% | —missing |
| Revenue / Invested capitalmultiple | 11.85× | -7.16× | 0.45× | 0.13× | 0× |
| Cogs Over Revenuesratio | 604.2% | 5,546.7% | 63,029% | 391,320% | —missing |
| Sga Over Revenuesratio | —missing | —missing | —missing | —missing | —missing |
| Da Over Revenuesratio | 2.7% | 22.8% | 276% | 1,530% | —missing |
| Nfa Over Revenuesratio | 29% | 167.7% | 1,325.3% | 7,680% | —missing |
| Wcr Over Revenuesratio | -20.5% | -181.6% | -1,101.3% | -6,910% | —missing |
| Debt Over Ebitdamultiple | —missing | —missing | —missing | —missing | —missing |
| St Debt Over Cashmultiple | 0.01× | 0.01× | 0.02× | 0.02× | 0.01× |
| Interest Over Ebitdamultiple | —missing | —missing | —missing | —missing | —missing |
| Interest Over Nocf Nicfmultiple | 0× | 0× | 0× | 0× | 0× |
| Nsf Over Wcrmultiple | 65.2× | 42.36× | 56.84× | 59.41× | 32.38× |
Ask this snapshot
Research assistant
4012B · annualSnapshot 4a1f83e1
Answers use only this published snapshot. The assistant will say when the data is insufficient and does not create forecasts, scenarios, or investment advice.
0 / 2,000